Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer
- K. Moore
- , N. Colombo
- , G. Scambia
- , B. G. Kim
- , A. Oaknin
- , M. Friedlander
- , A. Lisyanskaya
- , A. Floquet
- , A. Leary
- , G. S. Sonke
- , C. Gourley
- , S. Banerjee
- , A. Oza
- , A. González-Martín
- , C. Aghajanian
- , W. Bradley
- , C. Mathews
- , J. Liu
- , E. S. Lowe
- , R. Bloomfield
- University of Oklahoma
- University of Milan - Bicocca
- IRCCS
- Vall d'Hebron Institute of Oncology
- University of New South Wales
- St Petersburg City Oncology Dispensary
- Groupe D'Investigateurs Nationaux pour L'Etude des Cancers Ovariens
- Centre Georges-François Leclerc
- Gustave Roussy
- Netherlands Cancer Institute
- University of Edinburgh
- Royal Marsden NHS Foundation Trust
- Princess Margaret Cancer Centre
- University of Texas MD Anderson Cancer Center
- Memorial Sloan-Kettering Cancer Center
- Medical College of Wisconsin
- Women and Infants Hospital of Rhode Island
- Dana-Farber Cancer Institute
- AstraZeneca
Research output: Contribution to journal › Article › peer-review
2419
Link opens in a new tab
Scopus
citations